This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Delacrétaz, E. Articles by Brunner, H. R. Search for Related Content PubMed PubMed Citation Articles by Delacrétaz, E. Articles by Brunner, H. R.

(Hypertension. 1995;25:14-21.)
© 1995 American Heart Association, Inc.

Articles

Characterization of the Angiotensin II Receptor Antagonist TCV-116 in Healthy Volunteers

Etienne Delacrétaz; Jürg Nussberger; Jerôme Biollaz; Bernard Waeber; Hans R. Brunner

From the Division of Hypertension and the Division of Clinical Pharmacology (J.B.), University Hospital, Lausanne, Switzerland.

Correspondence to Hans R. Brunner, Division of Hypertension, CHUV, 1011 Lausanne, Switzerland.

Abstract The purpose of this study was to assess the inhibitory effect of TCV-116, an orally active angiotensin II (Ang II) antagonist, on the pressor action of exogenous Ang II and to determine the compensatory rise in plasma renin activity and Ang II levels. Twenty-three male volunteers were treated for 8 days in a double-blind fashion with either placebo or TCV-116 (1, 2, or 4 mg PO daily) and challenged on the first, fourth, and eighth days with repeated bolus injections of Ang II. An additional 4 subjects received 8 mg PO daily in a single-blind fashion. The inhibitory effect on the systolic blood pressure response to Ang II was long lasting and clearly dose related. Six hours after 4 mg TCV-116, the systolic blood pressure response to a given dose of Ang II was reduced to 40±4% and 35±8% of baseline value on days 1 and 8, respectively. TCV-116 induced a dose-related increase in plasma renin activity and Ang II levels that was more pronounced on the eighth than on the first day of drug administration. Despite this compensatory mechanism, the relation between the time-integrated systolic blood pressure response to Ang II and the time-integrated CV-11974 levels, the active metabolite of TCV-116, was not different between days 1 and 8. In conclusion, TCV-116 appears to be a well-tolerated, orally active, potent, and long-lasting antagonist of Ang II in men.

Key Words: angiotensin II • aldosterone • renin • dose-response relationship, drug

This article has been cited by other articles:

				V. P. Singh, B. Le, R. Khode, K. M. Baker, and R. Kumar Intracellular Angiotensin II Production in Diabetic Rats Is Correlated With Cardiomyocyte Apoptosis, Oxidative Stress, and Cardiac Fibrosis Diabetes, December 1, 2008; 57(12): 3297 - 3306. [Abstract] [Full Text] [PDF]

				J. A. Miller, D. Z. Cherney, J. A. Duncan, V. Lai, K. D. Burns, C. R.J. Kennedy, J. Zimpelmann, W. Gao, D. C. Cattran, and J. W. Scholey Gender Differences in the Renal Response to Renin-Angiotensin System Blockade J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2554 - 2560. [Abstract] [Full Text] [PDF]

				M. Azizi, A. Bissery, M. Lamarre-Cliche, and J. Menard Integrating Drug Pharmacokinetics for Phenotyping Individual Renin Response to Angiotensin II Blockade in Humans Hypertension, April 1, 2004; 43(4): 785 - 790. [Abstract] [Full Text] [PDF]

				D. Tran, S. Phoon, and L. Howes The effects of candesartan on vascular responses to angiotensin II and norepinephrine in normal volunteers Journal of Renin-Angiotensin-Aldosterone System, September 1, 2001; 2(3): 199 - 203. [Abstract] [PDF]

				G. Vauquelin, F. L. Fierens, I. Verheijen, and P. M. Vanderheyden Distinctions between non-peptide angiotensin II AT1-receptor antagonists Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S24 - S31. [Abstract] [PDF]

				W. F van Rodijnen, T. A van Lambalgen, M. E van Teijlingen, G.-J. Tangelder, and P. M ter Wee Comparison of the AT1-receptor blockers candesartan, irbesartan and losartan for inhibiting renal microvascular constriction Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S204 - S210. [Abstract] [PDF]

				M. Burnier Angiotensin II Type 1 Receptor Blockers Circulation, February 13, 2001; 103(6): 904 - 912. [Full Text] [PDF]

				L. Mazzolai, M. Maillard, J. Rossat, J. Nussberger, H. R. Brunner, and M. Burnier Angiotensin II Receptor Blockade in Normotensive Subjects : A Direct Comparison of Three AT1 Receptor Antagonists Hypertension, March 1, 1999; 33(3): 850 - 855. [Abstract] [Full Text] [PDF]

				J. H. Bauer and G. P. Reams The Angiotensin II Type 1 Receptor Antagonists: A New Class of Antihypertensive Drugs Arch Intern Med, July 10, 1995; 155(13): 1361 - 1368. [Abstract] [PDF]